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Abstract
Background: Extensively hydrolyzed casein formula (EHCF) has been proposed for
the prevention and is commonly used for the treatment of cow’s milk allergy (CMA).
The addition of the probiotic Lactobacillus rhamnosus GG (LGG) to EHCF may
induce faster acquisition of tolerance to cow’s milk. The mechanisms underlying this
effect are largely unexplored. We investigated the effects of EHCF alone or in
combination with LGG on b-lactoglobulin (BLG) sensitization in mice.
Methods: Three-week-old C3H/HeOuJ mice were sensitized by oral administration of
BLG using cholera toxin as adjuvant at weekly intervals for 5 weeks (sensitization
period). Two experimental phases were conducted: (i) EHCF or EHCF+LGG given
daily, starting 2 weeks before the sensitization period and then given daily for 5 weeks
and (ii) EHCF or EHCF+LGG given daily for 4 weeks, starting 1 week after the
sensitization period. Diet free of cow’s milk protein was used as control. Acute allergic
skin response, anaphylactic symptom score, body temperature, intestinal permeability,
anti-BLG serum IgE, and interleukin (IL)-4, IL-5, IL-10, IL-13, IFN-c mRNA
expression were analyzed. Peptide fractions of EHCF were characterized by reversed-
phase (RP)-HPLC, MALDI-TOF mass spectrometry, and nano-HPLC/ESI-MS/MS.
Results: Extensively hydrolyzed casein formula administration before or after BLG-
induced sensitization significantly reduced acute allergic skin reaction, anaphylactic
symptom score, body temperature decrease, intestinal permeability increase, IL-4,
IL-5, IL-13, and anti-BLG IgE production. EHCF increased expression of IFN-c and
IL-10. Many of these effects were significantly enhanced by LGG supplementation.
The peptide panels were similar between the two study formulas and contained
sequences that could have immunoregulatory activities.
Conclusions: The data support dietary intervention with EHCF for CMA prevention
and treatment through a favorable immunomodulatory action. The observed effects
are significantly enhanced by LGG supplementation.
Extensively hydrolyzed casein formula (EHCF) has been
proposed for CMA prevention in at-risk infants (1), and it is
commonly used as a first-line option for CMA treatment (2, 3).
The efficacy of extensively hydrolyzed formulas on food allergy
prevention is still controversial (4). Conversely, in a prospective
study of infants with confirmed CMA, treatment with EHCF
induced faster tolerance acquisition compared with other
available formulas (hydrolyzed rice formula, soy formula and
amino acid-based formula) (5). This effect was potentiated by
the addition of the probiotic Lactobacillus rhamnosus GG
(LGG) (5–7). Apart from being hypoallergenic, little is known
regarding a possible immunomodulatory role of the casein
hydrolysis-derived peptides against CMA, whether alone or in
combination with LGG. Immunomodulatory effects of EHCF
have been demonstrated in a rat model of type 1 diabetes (8),
suggesting possible similar effects against other
230 Pediatric Allergy and Immunology 28 (2017) 230–237 ª 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Pediatric Allergy and Immunology
immune-mediated conditions, such as food allergy. Murine
models have been adopted to investigate the immune mecha-
nisms elicited by different dietary interventions in CMA (9–12).
In this study, we investigated the mechanisms elicited by
EHCF, either alone or in combination with LGG, against
b-lactoglobulin (BLG) sensitization in mice. Peptide fractions




Three-week-old female C3H/HeOuJ mice were used for all
experiments (Charles River Laboratories, Calco, Lecco, Italy).
Mice were housed in the animal facility under a 12L:12D
lighting cycle, 20–24°C ambient temperature range, and 40–
70% relative humidity. The mice were acclimated to their
environment for 1 week before the experiments began. Each
treatment group received an isocaloric diet during all experi-
mental procedures (0.5 kcal/gr of body weight/day). All
procedures involving the animals were carried out in accor-
dance with the Institutional Guidelines and complied with the
Italian D.L. no.116 of January 27, 1992 of the Italian Ministry
of Health and associated guidelines in the European Commu-
nities Council Directive of November 24, 1986 (86/609/ECC)
and were approved by the Institutional Committee on the
Ethics of Animal Experiments (CSV) of the University of
Naples ‘Federico II’ and by the Ministero della Salute
(Protocol No. 2012-0024683).
Phase 1
The experimental design is reported in Fig. 1Sa. Briefly,
starting from 2 weeks prior to sensitization, mice were given
three different experimental diets: solid diet free of cow’s milk
protein (Harlan Laboratories, Udine, Italy), EHCF (Nutrami-
gen, Mead Johnson Nutrition, Evansville, IN, USA), or
EHCF+LGG (Nutramigen LGG1, Mead Johnson Nutrition,
Evansville, IN, USA). EHCF and EHCF+LGG formulas were
prepared daily by dissolving the powder in distilled water, as
indicated by the manufacturer, and were provided to the mice
in sterile bottles. The daily amount of formula consumed by
the mice was measured by subtracting the final bottle weight
from the baseline weight. The composition of the three
experimental diets is presented in Table S1. We used 4 of 5
mice per group in two independent experiments. After 14 days,
mice were sensitized orally using a blunt needle on day 0, 7, 14,
21, 28 with 20 mg of b-lactoglobulin (BLG) (Sigma-Aldrich,
Steinheim, Germany) in PBS (200 ll) mixed with 10 lg cholera
toxin (CT) (Sigma-Aldrich, Steinheim, Germany) as adjuvant
(13). One week after the final sensitization, acute allergic skin
response was assessed. On next day, rectal temperature was
measured, and then, mice were challenged by gavage with BLG
(50 mg in 200 ll of PBS). After 1 h, the anaphylaxis score was
assessed and rectal temperature was measured again. After
24 h, mice were sacrificed, blood samples were collected, and
mesenteric lymph nodes (MLN) were aseptically excised and
cryopreserved.
Phase 2
The experimental design is reported in Fig. 1Sb. Briefly, mice
fed with a solid cow’s milk protein-free diet were sensitized
orally as described above. One week after the final sensitiza-
tion, mice were given three different experimental diets: solid
diet free of cow’s milk protein, EHCF, or EHCF+LGG. We
used 4 of 5 mice per group in two independent experiments. At
the end of the 5-week treatment, mice were challenged and
sacrificed as described above.
Acute allergic skin response, anaphylaxis symptom score, and
body temperature
Acute allergic skin response was evaluated according to a
previously described procedure (14). The ear swelling was
calculated by correcting the allergen-induced ear thickness with
the basal ear thickness. The delta ear swelling was expressed as
lm.
Hypersensitivity symptoms were scored by an investigator
blind to the study group assignment 1 h after oral BLG
challenge, as previously described (12).
Body temperature was measured by rodent thermometer
(Bioseb, Valbonne, France).
Serum anti-BLG immunoglobulin E
Blood samples obtained from mice by intracardiac puncture
were collected in serum separator tubes. The serum portion
was separated by centrifugation at 10,000 9 g for 5 min at
20°C. Serum samples were then aliquoted into Eppendorf
tubes and stored at 20°C until analysis. The level of anti-
BLG serum IgE was detected by ELISA. Ninety-six-well
plates (Sigma-Aldrich, Steinheim, Germany) were coated with
100 lg/ml of BLG in 0.1 mol/l Na-bicarbonate/carbonate
coating buffer (pH 9.6). After overnight incubation at 4°C,
plates were washed three times with 150 ll of PBS plus 0.05%
Tween-20 (PBS-T) and blocked with 100 ll of 2% BSA in
PBS-T for 2 h at 37 °C. Subsequently, the plates were washed
three times, and 100 ll of serially diluted serum samples was
added to the wells and incubated at 37°C for 90 min. Plates
were then washed three times, and 100 ll of Biotin Rat-
anti-mouse IgE (BD Biosciences, Milano, Italy) was added to
each well. The plates were incubated at 37°C for 2 h and
washed five times. Then, 100 ll of horseradish peroxidase-
conjugated anti-mouse antibodies was added to each well and
the plates were again incubated at 37°C for another 60 min
and washed three times. Then, 100 ll of TMB (3, 30, 5,
50-tetramethyldiaminebenzidine) was added to each well and
15 min was allowed for the development of colorimetric
reactions. Absorbance was read at a wavelength of 450 nm in
a microplate reader.
Intestinal permeability in vivo
From each study group of both experimental phases, four
animals were used to investigate intestinal permeability with
4000 Da FITC-labeled dextran as previously described (15).
FITC-dextran concentration was determined by spectropho-
tometry (HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley,
Massachusetts, USA).
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Gene expression analysis by quantitative real-time PCR
Total RNA was isolated from mesenteric lymph nodes (MLN)
from mice by solubilization in TRIzol (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) and quantified using the
Nanodrop 2000c spectrophotometer (Thermo Scientific,
Waltham, MA, USA). For cDNA synthesis, 1 lg total RNA
was transcribed using the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. Quantita-
tive real-time PCR (qRT-PCR) analysis of IL-4, IL-5, IL-13,
IFN-c, and IL-10 was performed using TaqMan specific
probes (Applied Biosystems, Grand Island, NY, USA)
(Table S2). Samples were run in triplicate at 95°C for 30 s
followed by 40 cycles of 95°C for 10 s and 60°C for 30 s, using
a Light Cycler 7900HT (Applied Biosystems). Data analysis
was performed by comparative threshold cycle (CT) method.
The quantitative gene expression was calculated with the
comparative CT method and normalized against the CT of
glucuronidase (GUS) messenger as a reference gene.
Characterization of peptides from study formula
Peptide extraction
The EHCF powders (1.0 g) were defatted with hexane (10 mL,
twice), air-dried, and finally reconstituted in distilled water.
Peptides were purified by solid-phase extraction using a
Sep-Pak pre-packed C18 reversed-phase cartridge (Waters,
Milford, MA, USA), according to the manufacturer’s instruc-
tion. Peptides were eluted with 3 mL of 70% acetonitrile/0.1%
TFA, concentrated with a speed-vac, and finally lyophilized.
Reversed-phase (RP)-HPLC
Purified peptides were redissolved in 1.5 ml of 0.1%TFA and
fractionated by HPLC using a modular system HP 1100
(Agilent, Palo Alto, CA, USA) equipped with a 2.0 mm i.d. 9
250 mm, C18, 5 lm reversed-phase column (Phenomenex,
Torrance, CA, USA). Solvent A was 0.1% TFA in water, and
solvent B was 0.1% TFA in acetonitrile. Separations were
performed with a 5–65% gradient of solvent B over 60 min,
after a 5-min isocratic elution at 5% B at a constant flow rate
of 0.2 ml/min. The column effluents were monitored by UV
detection at wavelengths k = 214 and 280 nm. Approximately
40 lg of peptides was injected for each run. Post-run
elaboration was carried out using the HPLC off-line software
purchased with the instrument (Agilent, Palo Alto, CA,
USA).
MALDI-TOF mass spectrometry
The matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) analyses were
performed on a PerSeptive Biosystems Voyager DE-PRO
Figure 1 Phase 1 experiments. In vivo data. (a) acute allergic ear swelling response, (b) anaphylactic symptom score, (c) body temperature. In
vitro data. (d) intestinal permeability to plasma DX-4000 FITC and (e) anti-BLG-serum IgE. Data were analyzed with independent sample t-test.
*p < 0.05. Data represent pooled values from two separate experiments.
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instrument (Foster City, CA, USA), using a-cyano-4-hydroxy-
cinnamic acid matrix (10 mg/ml aqueous 50% acetonitrile/0.1%
TFA) as thematrix, as previously described (16). The spectrawere
analyzed with the Data Explorer software (version 4.0) provided
with the instrument (AppliedBiosystems, FosterCity,CA,USA).
Nano-HPLC/ESI-MS/MS
Nanoflow HPLC separations were carried out with an
Ultimate 3000 nano-HPLC system (Dionex, Sunnyvale, CA,
USA) equipped with a FAMOS Autosampler (Dionex).
Peptide extracts were redissolved in 0.1% (v/v) TFA at the
approximate concentration of 0.5 lg/lL, and 2.5 lL was
loaded onto a C18 trapping cartridge (LC Packings, Dionex,
USA) before separation on a capillary column (PepMap, C18,
5 lm, 300 A, 75 i.d.lm 915 cm, LC Packings, Dionex).
Peptides applying a linear gradient from 2% to 45% of
solution B over 90 min, following 10 min of isocratic elution at
2% of solution B, at a constant flow rate of 300 ml/min.
Solvent A was H2O containing 0.1% formic acid, and solvent B
was 0.08% formic acid in 80% acetonitrile (v/v).
Effluents were analyzed online using an electrospray hybrid
quadrupole/time-of-flight (ESI-Q-TOF) mass spectrometer (Q-
Star Pulsar, Applied BioSystems, Foster City, CA, USA), and
peptides were identified according to a previously described
procedure (16). Samples were analyzed in triplicate, and
peptides were included in the identification list if they occurred
in all replicates.
Statistical analysis
The Kolmogorov–Smirnov test was used to determine whether
continuous variables were normally distributed. All tests of
significance were two-sided. A p value of 0.05 was considered
significant. All analyses were conducted by a statistician
blinded to mice group assignment using SPSS release 20.0.0




BLG-sensitized mice showed a significantly higher acute
allergic skin response, anaphylactic symptom score, and body
temperature decrease compared to control animals. All of these
effects were significantly reduced by pre-treatment with EHCF.
The presence of LGG significantly increased the effect of
EHCF on allergic skin response. Similarly, BLG-sensitized
animals showed a significant increase in serum BLG-specific
IgE and intestinal permeability compared to control animals
(Fig. 1a–e). These effects were significantly inhibited by
EHCF. In addition, EHCF pre-treatment stimulated a signif-
icant increase in IL-10 and IFN-c expression correlated with
reduction in IL-4, IL-5, and IL-13 expression (Fig. 2a–e). The
presence of LGG significantly potentiated EHCF activities.
Figure 2 Phase 1 experiments. Cytokines expression in MNL (a) IL-4 relative expression, (b) IL-5 relative expression, (c) IL-13 relative
expression, (d) IL-10 relative expression, and (e) IFN-c relative expression. Data were analyzed with independent sample t-test. *p < 0.05. Data
represent pooled values from two separate experiments.
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Phase 2
EHCF treatment significantly reduced the acute allergic skin
response, anaphylactic symptom score, and body temperature
decrease compared to sensitized animals. The presence of LGG
induced more pronounced effects on all these variables.
Dietary treatment with EHCF induced a significant reduction
in anti-BLG IgE serum levels and intestinal permeability
increase (Fig. 3a–e). EHCF stimulated a significant reduction
in IL-4, IL-5, and IL-13 expression and an increase in IFN-c
and IL-10 expression (Fig. 4a–e). The presence of LGG
significantly enhanced all of these effects.
Characterization of peptides from study formulas
The RP-HPLC-UV comparison demonstrated similar peptide
profiles for EHCF and EHCF+LGG (Fig. 2Sa). This observa-
tion was confirmed by MALDI-TOF MS and nano-HPLC/
ESI-Q-TOF MS/MS analyses (not shown). Fig. 2Sb shows the
MALDI-TOF MS-based assignment of EHCF peptides. No
peptides longer that 12 residues were detected. Including a
previous chromatographic step, the nano-HPLC/ESI-Q-TOF
MS/MS analysis validated the MALDI-TOF MS results and
resulted in a more detail characterization including peptide
sequences. A comprehensive list of the peptides identified in the
two formulas is reported in Table S3. The highest number of
peptides (30 of 42, 71.5%) arose from b-casein, followed by
as1-casein (eight of 42, 19.0%) and j-casein (four of 42, 9.5%)
in line with previous observations (17). No fragments of whey
proteins were detected in the current study.
Discussion
The results of this study provide evidence that casein hydrolysis
not only deletes allergenic epitopes but also produces
immunoregulatory peptides that counteract allergic response.
The results of acute allergic skin response, anaphylactic
symptoms, body temperature, and intestinal permeability
demonstrate that EHCF inhibits oral BLG sensitization, at
least partly through a modulation of Th1/Th2 cytokine
expression. We observed an enhancement in IL-10 expression,
a major immune-regulatory cytokine that maintains mucosal
homeostasis and limits excessive immune responses against
dietary and bacterial antigens present in the intestinal lumen
(18). These findings are in keeping with the results of previous
clinical studies demonstrating a preventive effect against CMA
elicited by the same formula (19).
Figure 3 Phase 2 experiments. In vivo data. (a) acute allergic ear swelling response, (b) anaphylactic symptom score, (c) body temperature. In
vitro data. (d) intestinal permeability to plasma DX-4000 FITC, (e) anti-BLG-serum IgE, Data were analyzed with independent sample t-test.
*p < 0.05. Data represent pooled values from two separate experiments.
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Similar effects were obtained in mice treated with EHCF
after sensitization with BLG. Previous studies have demon-
strated that casein hydrolysis-derived peptides can inhibit
allergen uptake across the intestinal mucosa by inhibiting
either the production of specific IgE or the antigen binding
to IgE on mast cells (20–22). Moreover, these peptides
stimulate production of IL-10 by human lymphocytes (23)
and improve gut barrier function both in vivo and in vitro (8,
24). The largest number of EHCF peptides (71.5%) arose
from b-casein. Unlike in other investigations on casein-based
formulas, we did not detect any fragments of whey proteins
originating from contaminating BLG (16, 25). Several EHCF
peptides were detected that derived from two specific b-
casein domains, the C-terminal and b-casomorphin domains,
with a previously demonstrated immunoregulatory role (22,
26). Interestingly, many peptides shared the common amino
acid motif Pro-Phe-Pro (PFP) that occurs at the positions
61–63, 110–112, and 204–206 of b-casein. The PFP motif,
along with its peptide precursors, has been previously
indicated as the determinant of the immunoregulatory
activity of b-casein regions (27). Finally, b-casomorphin 7,
detected in EHCF, stimulates intestinal mucin production
(28). Mucus lubricates the intestinal surface and functions as
a dynamic defensive barrier limiting the access of luminal
molecules into the mucosa (29).
The peptide fractions of EHCF or EHCF+LGG were
similar, demonstrating that LGG is unable to elicit any
proteolytic action on immunoregulatory peptides. In addition,
in both experimental phases, many EHCF effects were
enhanced by the addition of LGG. An immunoregulatory
action by LGG, skewing toward a Th1 response, has been
already demonstrated in a murine model of CMA (30). LGG
is known to modulate immune functions via various path-
ways, including those involving enterocytes, monocytes, mast
cells, dendritic cells, and regulatory T cells (31). This probiotic
reduces proinflammatory cytokine-induced alteration of
intestinal permeability (31). These data further support
clinical evidence showing a more potent activity elicited by
EHCF containing LGG on gut inflammation (32) and on oral
tolerance acquisition in children affected by CMA (5–7).
In conclusion, the results of this study demonstrate that, in a
mouse model, EHCF exerts multiple immunoregulatory activ-
ities that efficiently counteract several mechanisms involved in
CMA pathogenesis and that the presence of LGG increases the
magnitude of many of these effects.
However, is important to underline that it is not possible to
make general statements on the immunomodulatory effects of
hydrolysates alone or in combination with probiotics. Every
hydrolysate is unique because materials and production meth-
ods differ among available hypoallergenic formulas (33), and
immunoregulatory effects elicited by probiotics are strain-
specific (34). This variability underscores the importance of
specific peptides and probiotic strains present in hypoallergenic
formulas.
Figure 4 Phase 2 experiments. Cytokines expression in MNL (a) IL-4 relative expression, (b) IL-5 relative expression, (c) IL-13 relative
expression, (d) IL-10 relative expression, and (e) IFN-c relative expression. Data were analyzed with independent sample t-test. *p < 0.05. Data
represent pooled values from two separate experiments.
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Supporting Information
Additional Supporting Information may be found in the online version of
this article:
Table S1. Composition of the experimental diets used in the study (9100 g).
Table S2. Probe details used for real–time PCR analysis.
Table S3. Comprehensive nano-HPLC-ESI MS/MS-based identification of
EHCF and EHCF + LGG peptides. PFP motif is highlighted in bold.
CN = casein.
Figure S1. Experimental design of (a) Phase 1, and (b) Phase 2 of the study.
Figure S2. Characterization of peptides from study formulas by (a) RP-
HPLC and (b) MALDI-TOF mass spectrum.
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